ATOSSA THERAPEUTICS INC. - COMMON STOCK

0,9441

31-декабря-24 16:45:00

15 мин. задержка

Акции

-0,0300

-3,08%

Сегодняшний диапазон

0,9130 - 1,0000

ISIN

N/A

Источник

NASDAQ

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

12 дек 2024 08:15:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

11 дек 2024 08:15:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

10 дек 2024 09:05:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

09 дек 2024 08:15:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

21 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

20 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

12 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

05 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

04 ноя 2024 06:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

31 окт 2024 08:15:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

21 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

14 окт 2024 17:08:43 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

01 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

10 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

28 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

21 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

20 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

22 июл 2024 08:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.